Business Description
Krystal Biotech Inc
NAICS : 325412
SIC : 2836
ISIN : US5011471027
Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 78.7 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 36.19 | |||||
| Beneish M-Score | 21.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | -10.1 | |||||
| 3-Year FCF Growth Rate | -18.5 | |||||
| 3-Year Book Growth Rate | 23 | |||||
| Future 3-5Y Total Revenue Growth Rate | 125.61 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.45 | |||||
| 9-Day RSI | 68.58 | |||||
| 14-Day RSI | 63.94 | |||||
| 6-1 Month Momentum % | 11.62 | |||||
| 12-1 Month Momentum % | 77.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.97 | |||||
| Quick Ratio | 7.76 | |||||
| Cash Ratio | 6.57 | |||||
| Days Inventory | 219.45 | |||||
| Days Sales Outstanding | 90.18 | |||||
| Days Payable | 100.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.7 | |||||
| Shareholder Yield % | -0.76 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.55 | |||||
| Operating Margin % | 26.89 | |||||
| Net Margin % | 21.69 | |||||
| FCF Margin % | 23.65 | |||||
| ROE % | 6.45 | |||||
| ROA % | 6 | |||||
| ROIC % | 22.13 | |||||
| ROC (Joel Greenblatt) % | 90.6 | |||||
| ROCE % | 21.39 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 110.91 | |||||
| Forward PE Ratio | 32.28 | |||||
| PE Ratio without NRI | 67.89 | |||||
| PS Ratio | 24.13 | |||||
| PB Ratio | 6.41 | |||||
| Price-to-Tangible-Book | 6.41 | |||||
| Price-to-Free-Cash-Flow | 101.87 | |||||
| Price-to-Operating-Cash-Flow | 93.21 | |||||
| EV-to-EBIT | 29.11 | |||||
| EV-to-Forward-EBIT | 19.9 | |||||
| EV-to-EBITDA | 28.15 | |||||
| EV-to-Forward-EBITDA | 19.9 | |||||
| EV-to-Revenue | 21.1 | |||||
| EV-to-Forward-Revenue | 10.24 | |||||
| EV-to-FCF | 87.79 | |||||
| Price-to-Projected-FCF | 42.83 | |||||
| Price-to-Graham-Number | 4.4 | |||||
| Price-to-Net-Current-Asset-Value | 9.21 | |||||
| Price-to-Net-Cash | 11.55 | |||||
| Earnings Yield (Greenblatt) % | 3.44 | |||||
| FCF Yield % | 1.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Krystal Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 221.11 | ||
| EPS (TTM) (€) | 1.624 | ||
| Beta | -0.53 | ||
| Volatility % | 57.75 | ||
| 14-Day RSI | 63.94 | ||
| 14-Day ATR (€) | 3.795392 | ||
| 20-Day SMA (€) | 173.2725 | ||
| 12-1 Month Momentum % | 77.91 | ||
| 52-Week Range (€) | 94.5 - 196.4 | ||
| Shares Outstanding (Mil) | 28.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Krystal Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Krystal Biotech Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Krystal Biotech Inc Frequently Asked Questions
What is Krystal Biotech Inc(FRA:4KB)'s stock price today?
The current price of FRA:4KB is €185.90. The 52 week high of FRA:4KB is €196.40 and 52 week low is €94.50.
When is next earnings date of Krystal Biotech Inc(FRA:4KB)?
The next earnings date of Krystal Biotech Inc(FRA:4KB) is 2025-02-26 Est..
Does Krystal Biotech Inc(FRA:4KB) pay dividends? If so, how much?
Krystal Biotech Inc(FRA:4KB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers